NewsBenzingaTakeda Presents Phase 3 Data Showing Once-Daily Oral Zasocitinib Delivers Higher PASI 100 At 36.5% Vs 13.9% And PASI 90 At 62.5% Vs 34.0% Than Deucravacitinib At Week 16; Under FDA, EMA Review For Plaque Psoriasis Takeda Presents Phase 3 Data Showing Once-Daily Oral Zasocitinib Delivers Higher PASI 100 At 36.5% Vs 13.9% And PASI 90 At 62.5% Vs 34.0% Than Deucravacitinib At Week 16; Under FDA, EMA Review For Plaque Psoriasis Benzinga 2026.09.30 06:52 (GMT+0) Open on Benzinga Other news Deutsche Bank Initiates Coverage On FormFactor with Buy Rating, Announces Price Target of $200 SBI, Mesh, Money Forward to Form Japan Digital Asset Joint Venture Full Transcript: Rockwell Automation Q3 2026 Earnings Call Meta avoided billions in federal taxes by classifying its data centers as experimental facilities Coinbase Receives CFTC Approval to Operate a Derivatives Clearing Organization Piper Sandler Maintains Overweight on Microsoft, Raises Price Target to $610
